Phages in the Fight Against COVID-19?

Górski, Andrzej; Międzybrodzki, Ryszard; Żaczek, Maciej; Borysowski, Jan

doi:10.2217/fmb-2020-0082

Cited by 28 publications

(36 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the advent of COVID-19, came several challenges one of which was therapeutics and several experimental therapeutics have been tried [ 5 ]. These have included antibiotics such as azithromycin among antivirals, and other therapies [ 6 ].…”

Section: Incidence and Risks Of CDI With Covid-19mentioning

confidence: 99%

The Interplay of SARS-CoV-2 and Clostridioides Difficile Infection

Khanna

Kraft

2021

Future Microbiol.

View full text Add to dashboard Cite

The COVID-19 pandemic has changed the way we practice medicine and lead our lives. In addition to pulmonary symptoms; COVID-19 as a syndrome has multisystemic involvement including frequent gastrointestinal symptoms such as diarrhea. Due to microbiome alterations with COVID-19 and frequent antibiotic exposure, COVID-19 can be complicated by Clostridioides difficile infection. Co-infection with these two can be associated with a high risk of complications. Infection control measures in hospitals is enhanced due to the COVID-19 pandemic which in turn appears to reduce the incidence of hospital-acquired infections such as C. difficile infection. Another implication of COVID-19 and its potential transmissibility by stool is microbiome-based therapies. Potential stool donors should be screened COVID-19 symptoms and be tested for COVID-19.

show abstract

Section: Incidence and Risks Of CDI With Covid-19mentioning

confidence: 99%

The Interplay of SARS-CoV-2 and Clostridioides Difficile Infection

Khanna

Kraft

2021

Future Microbiol.

View full text Add to dashboard Cite

show abstract

“…As increased levels of TNF are in blood samples and tissue from patients with COVID-19 may be inhibit TNF production through phage, which is confirmed by other author's previous reports that showed phage may down regulate TNF-α level in serum and lungs of mice with experimental acute pneumonia. Interestingly, clinical phage therapy may reduce TNF production when its pre-treatment level is high and increase it in low responders [45,46]. These informations might be considered as a relevant argument for phages as a potential agent that could help to decrease TNF levels, allowing for appropriate antiviral immune responses in COVID-19 while reducing the risks of excessive immunosuppression.…”

Section: Phages As Potential Inducers Of Antiviral Immunitymentioning

confidence: 99%

“…According to Gorskiet et al phage in COVID-19 could be in an adjunct antiviral therapy, which is quite similar to the current trend ofcombined phages with antibacterial treatment in bacterial infections. In other way, a standard phage therapy could be considered for the treatment of bacterial complications of COVID-19, which occur in >40% of patients [45,50]. Phages may act as shield for eukaryotic cells by competing with surface assimilation and viral penetration of cells; virus mediated, programmed cell death as well as viral replica.…”

Section: [Induction Of Antiviral Immune Response Through Recognition Of the Repeating Subunit Pattern Of Viral Capsid Is Toll-like Receptmentioning

confidence: 99%

Role of Phage Therapy in COVID-19 Infection: Future Prospects

Singh¹,

Gaur²,

Kumar³

2021

Bacteriophages in Therapeutics

View full text Add to dashboard Cite

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan City, China, in 2019. After that, the outbreak has grown into a global pandemic and definite treatment for the disease, termed coronavirus disease 2019 (COVID-19), is currently unavailable. The slow translational progress in the field of research suggests that a large number of studies are urgently required for targeted therapy. In this context, this hypothesis explores the role of bacteriophages on SARS-CoV-2, especially concerning phage therapy (PT). Several studies have confirmed that in addition to their antibacterial abilities, phages also show antiviral properties. It has also been shown that PT is effective for building immunity against viral pathogens by reducing the activation of NF kappa B; additionally, phages produce the antiviral protein phagicin. Phages can also induce antiviral immunity by upregulating expression of defensin 2. Phages may protect eukaryotic cells by competing with viral adsorption and viral penetration of cells, virus mediated cell apoptosis as well as replication. Moreover, by inhibiting activation of NF-κB and ROS production, phages can down regulate excessive inflammatory reactions relevant in clinical course of COVID-19. In this chapter, we hypothesize that the PT may play a therapeutic role in the treatment of COVID-19.

show abstract

“…Nevertheless, further studies need to be done to conclude whether phages have the potential to at least be an adjunct treatment of the SARS-CoV-2 infection. 40 …”

Section: Shotgun Metagenomics To Perceive the Microbiome In Patients mentioning

confidence: 99%

Metagenomics Approaches to Investigate the Gut Microbiome of COVID-19 Patients

Sehli

Allali

Chahboune

et al. 2021

Bioinform Biol Insights

View full text Add to dashboard Cite

Over the last decade, it has become increasingly apparent that the microbiome is a central component in human well-being and illness. However, to establish innovative therapeutic methods, it is crucial to learn more about the microbiota. Thereby, the area of metagenomics and associated bioinformatics methods and tools has become considerable in the study of the human microbiome biodiversity. The application of these metagenomics approaches to studying the gut microbiome in COVID-19 patients could be one of the promising areas of research in the fight against the SARS-CoV-2 infection and disparity. Therefore, understanding how the gut microbiome is affected by or could affect the SARS-CoV-2 is very important. Herein, we present an overview of approaches and methods used in the current published studies on COVID-19 patients and the gut microbiome. The accuracy of these researches depends on the appropriate choice and the optimal use of the metagenomics bioinformatics platforms and tools. Interestingly, most studies reported that COVID-19 patients’ microbiota are enriched with opportunistic microorganisms. The choice and use of appropriate computational tools and techniques to accurately investigate the gut microbiota is therefore critical in determining the appropriate microbiome profile for diagnosis and the most reliable antiviral or preventive microbial composition.

show abstract

Phages in the Fight Against COVID-19?

Abstract: recent progress in our understanding of phage immunobiology opens perspectives for the repurposing of phage therapy to clinical indications other than bacterial infections alone. "

Cited by 28 publications

References 46 publications

The Interplay of SARS-CoV-2 and Clostridioides Difficile Infection

The Interplay of SARS-CoV-2 and Clostridioides Difficile Infection

Role of Phage Therapy in COVID-19 Infection: Future Prospects

Metagenomics Approaches to Investigate the Gut Microbiome of COVID-19 Patients

Contact Info

Product

Resources

About